<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03194737</url>
  </required_header>
  <id_info>
    <org_study_id>CP00004</org_study_id>
    <nct_id>NCT03194737</nct_id>
  </id_info>
  <brief_title>Prostatic Urethral Lift in Subject With Acute Urinary Retention</brief_title>
  <official_title>Prostatic Urethral Lift in Subject With Acute Urinary Retention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeoTract, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeoTract, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess feasibility and safety of the Prostatic Urethra Lift (PUL) procedure in patients with&#xD;
      acute urinary retention secondary to benign prostatic hyperplasia (BPH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multi-centre, prospective evaluation of PUL and retrospective review of&#xD;
      invasive surgery as potential comparator. The study is intended to be conducted at up to 5&#xD;
      different centres in the United Kingdom to enrol up to 50 subjects. Subject follow-up visits&#xD;
      are at post-procedure, 6 weeks, 3 months, 6 months and 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2018</start_date>
  <completion_date type="Actual">March 3, 2020</completion_date>
  <primary_completion_date type="Actual">January 21, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Trial Without Catheter Peri-procedurally</measure>
    <time_frame>3 days (± 1 day) from index procedure</time_frame>
    <description>Success is defined as a spontaneous voided volume of ≥100 mL associated with a post void residual volume by ultrasound &lt;300 mL 3 days (± 1 day) after the index procedure catheter placement without the need for re-catheterisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events Related to Benign Prostatic Hyperplasia (BPH) Intervention</measure>
    <time_frame>Through 3 months</time_frame>
    <description>Number of patients who experienced adjudicated Serious Adverse Events related to Benign prostatic hyperplasia (BPH) Intervention Procedure or Device</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Acute Urinary Retention</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>UroLift System procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible,enroled subjects will undergo a UroLift procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UroLift System Procedure</intervention_name>
    <description>Minimally invasive procedure in patients with acute urinary retention secondary to BPH.</description>
    <arm_group_label>UroLift System procedure</arm_group_label>
    <other_name>Prostatic UroLift (PUL)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        UroLift System Procedure Arm&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Male gender&#xD;
&#xD;
          2. Diagnosis of symptomatic BPH&#xD;
&#xD;
          3. Age ≥ 50 years&#xD;
&#xD;
          4. Prostate volume ≤ 100 cc per ultrasound (US)&#xD;
&#xD;
          5. Acute urinary retention with at least one failed trial without catheter (TWOC) while&#xD;
             on alpha blocker&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. An obstructive or protruding median lobe of the prostate&#xD;
&#xD;
          2. Previous BPH surgical procedure&#xD;
&#xD;
          3. Previous pelvic surgery&#xD;
&#xD;
          4. Urethral conditions that prevents insertion and delivery of device system into bladder&#xD;
&#xD;
          5. Retention volume of &gt;1500 mL&#xD;
&#xD;
          6. Has not had prostate cancer excluded&#xD;
&#xD;
          7. History of prostate or bladder cancer&#xD;
&#xD;
          8. Biopsy of the prostate within the 6 weeks prior to Index Procedure&#xD;
&#xD;
          9. History of neurogenic or atonic bladder&#xD;
&#xD;
         10. Acute or chronic renal failure&#xD;
&#xD;
         11. Known coagulopathies or subject on anticoagulants within 3 days of index procedure&#xD;
             (excluding up to 100mg ASA)&#xD;
&#xD;
         12. Known bladder stones within the prior 3 months or treatment within 12 months&#xD;
&#xD;
         13. Prostatitis requiring treatment (antibiotics) within the last year&#xD;
&#xD;
         14. Other co-morbidities that could impact the study results&#xD;
&#xD;
               -  severe cardiac arrhythmias uncontrolled by medications or pacemaker&#xD;
&#xD;
               -  congestive heart failure New York Heart Association (NYHA) III or IV&#xD;
&#xD;
               -  history of uncontrolled diabetes mellitus&#xD;
&#xD;
               -  significant respiratory disease in which hospitalisation may be required&#xD;
&#xD;
               -  known immunosuppression (i.e. AIDS, post-transplant, undergoing chemotherapy)&#xD;
&#xD;
         15. Life expectancy estimated to be less than 5 years&#xD;
&#xD;
         16. Desire to maintain fertility post procedure&#xD;
&#xD;
         17. Unable or unwilling to complete all required questionnaires and follow up assessments&#xD;
&#xD;
         18. Unable or unwilling to sign informed consent form&#xD;
&#xD;
         19. Currently enroled in any other clinical research trial that has not completed the&#xD;
             primary endpoint&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Barber</last_name>
    <role>Principal Investigator</role>
    <affiliation>Frimley Park Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oliver Kayes</last_name>
    <role>Principal Investigator</role>
    <affiliation>St James's University Hosptial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Rochester</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research and Trials Unit (Norfolk &amp; Norwich University Hospital, UK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Toby Page</last_name>
    <role>Principal Investigator</role>
    <affiliation>Freeman Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajesh Kavia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Middlesex Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikesh Thiruchelvam</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>High Heaton</city>
        <state>Newcastle Upon Tyne</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frimley Park Hospital</name>
      <address>
        <city>Frimley</city>
        <state>Surrey</state>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Middlesex Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <results_first_submitted>May 6, 2021</results_first_submitted>
  <results_first_submitted_qc>July 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2021</results_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benign prostatic hyperplasia</keyword>
  <keyword>BPH</keyword>
  <keyword>Urinary retention</keyword>
  <keyword>prostate</keyword>
  <keyword>hypertrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Urinary Retention</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03194737/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03194737/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Retrospective cohort enrollment was separate from the 52 enrolled in the prospective cohort. Retrospective enrollment was based on a retrospective chart review between Jun 1, 2015 and December 31, 2015.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>UroLift System Procedure</title>
          <description>All eligible,enroled subjects will undergo a UroLift procedure.&#xD;
UroLift System Procedure: Minimally invasive procedure in patients with acute urinary retention secondary to BPH.</description>
        </group>
        <group group_id="P2">
          <title>Retrospective Arm</title>
          <description>Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>UroLift System Procedure</title>
          <description>All eligible,enroled subjects will undergo a UroLift procedure.&#xD;
UroLift System Procedure: Minimally invasive procedure in patients with acute urinary retention secondary to BPH.</description>
        </group>
        <group group_id="B2">
          <title>Retrospective Arm</title>
          <description>Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.3" spread="7.9"/>
                    <measurement group_id="B2" value="72.7" spread="8.0"/>
                    <measurement group_id="B3" value="72.0" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Lower Urinary Tract Symptoms (LUTS)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;1 year</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1-5 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6-10 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=10 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Successful Trial Without Catheter Peri-procedurally</title>
        <description>Success is defined as a spontaneous voided volume of ≥100 mL associated with a post void residual volume by ultrasound &lt;300 mL 3 days (± 1 day) after the index procedure catheter placement without the need for re-catheterisation.</description>
        <time_frame>3 days (± 1 day) from index procedure</time_frame>
        <population>Trial Without Catheter information for retrospective arm was recorded as available from medical record, information from the UroLift System was prospectively collected</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible, enrolled subjects will undergo a UroLift procedure.&#xD;
UroLift System Procedure: Minimally invasive procedure in patients with acute urinary retention secondary to BPH.</description>
          </group>
          <group group_id="O2">
            <title>Retrospective Arm</title>
            <description>Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Trial Without Catheter Peri-procedurally</title>
          <description>Success is defined as a spontaneous voided volume of ≥100 mL associated with a post void residual volume by ultrasound &lt;300 mL 3 days (± 1 day) after the index procedure catheter placement without the need for re-catheterisation.</description>
          <population>Trial Without Catheter information for retrospective arm was recorded as available from medical record, information from the UroLift System was prospectively collected</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events Related to Benign Prostatic Hyperplasia (BPH) Intervention</title>
        <description>Number of patients who experienced adjudicated Serious Adverse Events related to Benign prostatic hyperplasia (BPH) Intervention Procedure or Device</description>
        <time_frame>Through 3 months</time_frame>
        <population>Retrospective arm events were recorded from medical record and was not prospectively collected by sites compared to events collected prospectively from the UroLift System</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift System Procedure</title>
            <description>All eligible, enrolled subjects will undergo a UroLift procedure.&#xD;
UroLift System Procedure: Minimally invasive procedure in patients with acute urinary retention secondary to BPH.</description>
          </group>
          <group group_id="O2">
            <title>Retrospective Arm</title>
            <description>Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events Related to Benign Prostatic Hyperplasia (BPH) Intervention</title>
          <description>Number of patients who experienced adjudicated Serious Adverse Events related to Benign prostatic hyperplasia (BPH) Intervention Procedure or Device</description>
          <population>Retrospective arm events were recorded from medical record and was not prospectively collected by sites compared to events collected prospectively from the UroLift System</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Index procedure and up to 1 year</time_frame>
      <desc>An AE is defined as any undesirable medical occurrence in a clinical trial subject, whether it is considered to be related to the device or not, that includes a clinical sign, symptom, or condition An (SAE) is defined as untoward occurrence that:(a) death; (b) life-threatening; (c) requires hospitalisation or prolongation of existing hospitalisation (d) results in persistent or significant disability or incapacity; or (e) is otherwise considered medically significant by the investigator</desc>
      <group_list>
        <group group_id="E1">
          <title>UroLift System Procedure</title>
          <description>All eligible,enroled subjects will undergo a UroLift procedure.&#xD;
UroLift System Procedure: Minimally invasive procedure in patients with acute urinary retention secondary to BPH.</description>
        </group>
        <group group_id="E2">
          <title>Retrospective Arm</title>
          <description>Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lucunar stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood clot in urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency (Pollakiuria)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Incontinence urge</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator agreements restrict data disclosure until written agreement by or publication by Sponsor</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data Retrospectively collected from the invasive Benign prostatic hyperplasia (BPH) surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) was not directly comparable to the prospective UroLIFT system outcomes because of inherent standard of care differences between interventions, standard of care at sites and recording in medical records</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Emily Friedland, Director, Global Clinical Operations</name_or_title>
      <organization>Teleflex/NeoTract</organization>
      <phone>925.387.6014</phone>
      <email>emily.friedland@teleflex.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

